FLORHAM PARK, N.J., May 13, 2020 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious.

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that James Loughlin has resigned from the Company’s board of directors to focus on his health and family, effective immediately. PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Using Versamune®, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors.

PRINCETON, N.J., March 27, 2020 -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies.

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has appointed Kamil Ali-Jackson, Esq. Ms. Ali-Jackson will be a member of the Board’s audit committee.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Class A Common Stock(NYSE: BIO) • Capricor Therapeutics Inc (NASDAQ: CAPR)( reacted to data that showed a 100% survival rate in COVID-19 patients treated with its CAP-1002 cell therapy) • Cue Biopharma Inc (NASDAQ: CUE) • DexCom, Inc. (NASDAQ: DXCM)(reacted to its quarterly results) • Erytech Pharma SA (NASDAQ: ERYP)(announced Fast Track Designation from the FDA for its cancer drug in pancreatic cancer) • GenMark Diagnostics, Inc (NASDAQ: GNMK) • I-Mab ADR (NASDAQ: IMAB) • Immunomedics, Inc. (NASDAQ: IMMU) • Keros Therapeutics Inc (NASDAQ: KROS) • Masimo Corporation (NASDAQ: MASI)(announced solid first-quarter results) • Mersana Therapeutics Inc (NASDAQ: MRSN) • Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) • Zynex Inc. (NASDAQ: ZYXI)(announced its first-quarter results)None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Wednesday.Stocks In Focus Marker's Leukemia Drug Candidate Gets Orphan Drug Designation Marker Therapeutics, Inc. (NASDAQ: MRKR) said the FDA accorded Orphan Drug Designation to MT-401, its multi-tumor-associated antigen-specific T cell product for the treatment of patients with acute myeloid leukemia following allogenic stem cell transplant.In after-hours trading, the stock rallied 23.79% to $2.81.Evotec Unit to Work With Ology to Develop Antibodies Against Coronavirus German biopharma Evotec SE (OTC: EVOTF) said its Seattle-based subsidiary Just-Evotec Biologics has entered into a partnership with Ology Bioservices for the evaluation and analytical characterisation of antibodies against SARS-CoV-2 - the virus that causes COVID-19.The company noted this work was based on a contract awarded to Ology by the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies to develop, and manufacture monoclonal antibodies for the treatment and prevention of infections with SARS-CoV-2FDA Approves an Expanded Indication For GlaxoSmithKline's Ovarian Cancer Drug GlaxoSmithKline plc (NYSE: GSK) announced FDA approval for its sNDA for Zejula as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker statusThe stock was up 1.51% to $42.48 in pre-market trading.PDS Biotech Announces Expansion to Cancer Drug Collaboration With NCI PDS Biotechnology Corp (NASDAQ: PDSB) announced an expansion of its previously announced Cooperative Research and Development Agreement with the National Cancer Institute to include studies of PDS0103, a Versamune-based product incorporating novel mucin-1 epitopes developed by the NCI.NCI is already evaluating PDS0101 in combination with two separate immune-modulating agents - NHS-IL12 and M7824 - in a phase 2 clinical trial in advanced HPV-associated cancers.The stock was adding 2.61% to 97 cents in pre-market trading.BeiGene, IGM, Atreca To Work On Coronavirus Treatment Atreca Inc (NASDAQ: BCEL), Beigene Ltd (NASDAQ: BGNE) and IGM Biosciences Inc (NASDAQ: IGMS) announced plans to collaborate to develop novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The companies said work will commence immediately, with the financial and other terms to be finalized in the future.In pre-market trading, BeiGene was edging up 0.42% to $162.30 and Atreca was advancing 3.57% to $18.Offerings NeoGenomics, Inc. (NASDAQ: NEO) priced its proposed underwritten public offerings of 4.4 million newly issued shares at $28.50 per share. The company also said it's offering $175 million in aggregate principal amount of its 1.25% convertible senior notes due 2025.The company also said underwriters of the common stock offering are also offering 1.065 million worth of shares of NeoGenomics borrowed from third parties.View more earnings on IBBThe stock slid 4.90% to $29.50 in after-hours trading.Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced plans to offer shares of its common stock in an underwritten public offering. All the shares are being offered by the company.In pre-market trading, the stock was adding 0.27% to $18.75.Earnings Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported first-quarter revenues of $1.52 million, up from $858.44 million in the year-ago quarter. On a non-GAAP basis, earnings per share, or EPS, climbed from $1.14 to $2.56, ahead of the $1.84 per share consensus estimate. The company upwardly revised its full-year net product revenue guidance.The stock was adding 2.97% to $258.50 in pre-market trading.Hologic, Inc.'s (NASDAQ: HOLX) second-quarter revenues fell 7.6% to $756.1 million, primarily reflecting Cynosure divestiture. The company reported non-GAAP EPS of 57 cents, in line with the consensus. The company withdrew its guidance for the second quarter and full year.Separately, the company said it plans to launch a new Aptima molecular assay to detect the SARS-CoV-2 virus that will run on its market-leading Panther system. The company expects to begin distributing a Research Use Only version of its test next week. It also plans to apply for Emergency Use Authorization with the FDA next week and register a CE Mark for diagnostic use in Europe later in May.In pre-market trading, the stock was jumping 9.07% to $53.39.Amarin Corporation plc's (NASDAQ: AMRN) first-quarter revenues climbed 112% to $155 million. The net loss per share on a non-GAAP basis narrowed from 5 cents to 3 cents. The results trumped the consensus that called for a loss of 7 cents per share on revenues of $137.43 million.Regarding the ANDA litigation, the company said hearing could happen in the third quarter or early fourth quarter, with a ruling likely in 2020 or in early 2021.Amarin said it believes that it has a strong basis for appeal, which will be set out in its opening brief proposed for filing on May 12th.In pre-market trading, Amarin shares were rallying 3.75% to $8.57.On The Radar Earnings • Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open) • ABIOMED, Inc. (NASDAQ: ABMD) (before the market open) • Baxter International Inc (NYSE: BAX) (before the market open) • BIO-TECHNE Corp (NASDAQ: TECH) (before the market open) • Genocea Biosciences Inc (NASDAQ: GNCA) (before the market open) • Novocure Ltd (NASDAQ: NVCR) (before the market open) • Syneos Health Inc (NASDAQ: SYNH) (before the market open) • PRA Health Sciences Inc (NASDAQ: PRAH) (before the market open) • Lantheus Holdings Inc (NASDAQ: LNTH) (before the market open) • Iradimed Corp (NASDAQ: IRMD) (before the market open) • Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open) • Amgen, Inc. (NASDAQ: AMGN) (after the close) • Emergent Biosolutions Inc (NYSE: EBS) (after the close) • Insmed Incorporated (NASDAQ: INSM) (after the close) • Gilead Sciences, Inc. (NASDAQ: GILD) (after the close) • Seattle Genetics, Inc. (NASDAQ: SGEN) (after the close) • Natus Medical Inc (NASDAQ: NTUS) (after the close) • Illumina, Inc. (NASDAQ: ILMN) (after the close) • PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close) • LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close) • ResMed Inc. (NYSE: RMD) (after the close) • Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) • Silk Road Medical Inc (NASDAQ: SILK) (after the close) • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) • CareDx Inc (NASDAQ: CDNA) (after the close) • Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close) • Ekso Bionics Holdings Inc (NASDAQ: EKSO) (after the close)See more from Benzinga * The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda * The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update * The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present at the 2020 BIO CEO & Investor Conference being held on February 10-11, 2020 at the Marriott Marquis in New York, NY. A live webcast of the presentation may be accessed on the Company's website at pdsbiotech.com or directly here. PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology platform.

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced commencement of work under an Amended and Restated Material Transfer Agreement with Farmacore Biotechnology, experts in infectious diseases, to develop a novel tuberculosis (TB) immunotherapy based on Farmacore’s proprietary TB antigens and PDS Bio’s Versamune® platform technology. The prior Material Transfer Agreement under which preliminary work commenced was Amended and Restated in December 2019 due to promising early pre-clinical results and to progress this next phase of development.

PDS Biotechnology Corporation (“PDS Biotechnology”) (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® today announced that it has appointed Ilian Iliev, Ph.D. to its Board of Directors. “Together, we will help guide PDS Biotech through its near and long-term milestones as we advance our programs in infectious disease and immuno-oncology with leading research institutions and pharmaceutical companies.”

PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the publication of its abstract on preclinical studies of PDS0102 at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program being held May 29-31, 2020. Versamune® is a proprietary T-cell activating platform technology designed to train the immune system to detect and attack cancer cells. The published data demonstrate that Versamune®, when combined with the proprietary T-cell receptor gamma alternate reading frame protein (TARP), has the ability to activate a powerful killer T-cell response which specifically recognizes and attacks TARP-expressing cancer cells.

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Jared Weiss, an internationally recognized expert in the field of thoracic and head and neck cancers and Faculty at the University of North Carolina at Chapel Hill School of Medicine and Lineberger Comprehensive Cancer Center, will be the Principal Investigator for the Company’s Phase 2 VERSATILE-002 study in collaboration with Merck. In addition, the Company has established an independent Data Monitoring Committee (DMC) that will be responsible for reviewing and evaluating patient safety and efficacy data in the upcoming Phase 2 study.

FLORHAM PARK, N.J., May 04, 2020 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious.

PRINCETON, N.J., March 23, 2020 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s.

PDS Biotechnology (PDSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced an expansion of its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to include studies of PDS0103, a Versamune®-based product incorporating novel mucin-1 (MUC1) epitopes developed by the NCI. This expansion adds to the NCI’s ongoing evaluation of PDS0101 in combination with two separate immune-modulating agents, NHS-IL12 and M7824, which will be evaluated in a phase 2 clinical trial in advanced HPV-associated cancers (NCT04287868). Under the expanded CRADA, PDS Biotech will collaborate with the NCI Center for Cancer Research’s Genitourinary Malignancies Branch (GMB) and the Laboratory of Tumor Immunology and Biology (LTIB) to conduct preclinical studies of PDS0103, and potentially human clinical studies in combination with other therapeutic agents.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 9,230,770 shares of common stock at a public offering price of $1.30 per share. The net proceeds to PDS Biotechnology from this offering, after deducting underwriting discounts, commissions were approximately $11 million and does not include other offering expenses. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website, located at www.sec.gov.

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has been granted U.S. Patent No. 15/702,063 titled “Stimulation of an Immune Response by Enantiomers of Cationic Lipids” by the United States Patent and Trademark Office (USPTO). "As we advance our lead program, PDS0101 towards three Phase 2 studies this year with leaders in the field of immuno-oncology, we believe that our Versamune® platform holds the potential to significantly improve clinical outcomes for patients.”

PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer and Dr. Lauren Wood, Chief Medical Officer are scheduled to participate in Noble Capital Markets' 16th Annual Small & Microcap Investor Conference being held on February 16-18, 2020 at the Seminole Hard Rock Hotel & Casino in Hollywood, FL. A live webcast of the corporate presentation may be accessed on the Company's website at pdsbiotech.com or directly here.

PDS Biotechnology Corporation (“PDS Biotechnology”) (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on PDS Biotechnology’s proprietary Versamune® T-cell activating technology, today announced the pricing of an underwritten public offering consisting of 9,230,770 shares of common stock at a price to the public of $1.30 per share. The gross proceeds to PDS Biotechnology from this offering are expected to be approximately $12,000,000, before deducting underwriting discounts, commissions and other offering expenses.

PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced an expanded infectious disease pandemic development program, including novel vaccines for COVID-19 and universal influenza, in addition to its previously announced tuberculosis development collaboration with Farmacore Biotechnology. The Company also announced that initiation of its multi-center Phase 2 VERSATILE-002 trial for PDS0101 in advanced/metastatic head and neck cancer has been delayed due to the severe adverse impact on clinical trial operations from the COVID-19 pandemic.